Pain Beliefs and Intracortical Excitability During Experimental Pain
Influence Of Pain-Related Beliefs On The Modulation Of Intracortical Circuits During Experimental Pain Induced By Topical Capsaicin
Pain can influence the way the motor system functions. However, responses to pain vary widely between individuals, and this variability may be partly related to pain-related beliefs such as kinesiophobia.
This study examines whether temporary experimental pain changes intracortical excitability in the motor cortex, and whether this response differs according to baseline kinesiophobia. Healthy adults will complete one experimental session. Motor cortex excitability will first be assessed at baseline using transcranial magnetic stimulation, a non-invasive brain stimulation technique. A topical capsaicin cream will then be applied to the forearm to induce temporary, moderate experimental pain. Once pain is established, the same neurophysiological assessments will be repeated.
The main objective is to measure changes in short-interval intracortical inhibition before and during capsaicin-induced pain, with particular attention to whether these changes are associated with baseline kinesiophobia.
Secondary objectives are to characterize other markers of motor cortex excitability, including long-interval intracortical inhibition, short-interval intracortical facilitation, intracortical facilitation, and corticospinal excitability assessed using input-output recruitment curves. Pain intensity will be monitored using a visual analog scale to characterize the experimental pain response. Baseline kinesiophobia will be assessed using the Tampa Scale of Kinesiophobia and examined as a factor associated with interindividual variability in neurophysiological responses to experimental pain.
The researchers expect that changes in motor cortex excitability during experimental pain will vary between individuals, and that individuals with higher kinesiophobia may show smaller changes in motor cortex excitability during capsaicin-induced pain.
調査の概要
詳細な説明
Pain is not only a sensory experience. It is also influenced by psychological, emotional, and contextual factors, including how people interpret pain and the threat they associate with movement. In the presence of pain, individuals often modify the way they move. These adaptations may be protective in the short term, but when maintained over time, they may contribute to persistent movement avoidance and disability.
Within the fear-avoidance framework, kinesiophobia, or fear of movement, is considered an important factor in the relationship between pain, movement, and disability. Individuals with higher kinesiophobia may perceive movement as threatening or potentially harmful. This may influence not only motor behavior, but also the way the nervous system prepares and controls movement. However, the neurophysiological mechanisms linking pain-related beliefs, experimental pain, and motor control remain incompletely understood.
The primary motor cortex is a key brain region involved in voluntary movement. Its excitability can be assessed using transcranial magnetic stimulation, a non-invasive brain stimulation technique. When applied over the primary motor cortex, transcranial magnetic stimulation can evoke motor responses that are recorded from a target muscle using surface electromyography. These responses provide information about corticospinal excitability and about intracortical inhibitory and facilitatory mechanisms.
Previous studies suggest that experimental pain can modify motor cortex excitability, but the direction and magnitude of these changes vary considerably between individuals. Pain-related beliefs, especially kinesiophobia, may partly explain this variability. This study therefore focuses on whether experimental pain changes intracortical excitability in the motor cortex and whether this response differs according to baseline kinesiophobia.
The main objective is to quantify changes in short-interval intracortical inhibition before and during experimental pain induced by topical capsaicin, with particular attention to whether these changes vary according to the participant's baseline level of kinesiophobia. Short-interval intracortical inhibition is used as the primary neurophysiological measure because it reflects inhibitory activity within the motor cortex.
Secondary objectives are to characterize other markers of motor cortex excitability during experimental pain. These include long-interval intracortical inhibition, intracortical facilitation, and corticospinal excitability assessed using input-output recruitment curves. These complementary measures are included to provide a broader characterization of inhibitory, facilitatory, and corticospinal responses to experimental pain.
Healthy adults will complete one experimental session. At the beginning of the session, participants will complete questionnaires assessing pain-related beliefs, including kinesiophobia. Baseline neurophysiological assessments will then be performed using transcranial magnetic stimulation applied over the primary motor cortex, with electromyographic recordings from the first dorsal interosseous muscle of the hand.
After baseline measurements, topical capsaicin cream will be applied to the forearm to induce temporary, moderate experimental pain. Pain intensity will be monitored using a visual analog scale. Once experimental pain is established, the same transcranial magnetic stimulation assessments will be repeated.
Each participant serves as their own control, with neurophysiological measures compared between the baseline condition and the experimental pain condition. The investigators hypothesize that changes in motor cortex excitability during experimental pain will vary between individuals. This variability is expected to be partly related to kinesiophobia, with individuals reporting higher kinesiophobia showing smaller changes in motor cortex excitability during capsaicin-induced pain.
研究の種類
入学 (推定)
段階
- 適用できない
連絡先と場所
研究連絡先
- 名前:Guillaume Léonard, Ph.D.
- 電話番号:819-821-8000
- メール:guillaume.leonard2@usherbrooke.ca
研究連絡先のバックアップ
- 名前:Adrien Nourry
- 電話番号:+33611074458
- メール:adrien.nourry@usherbrooke.ca
研究場所
-
-
Quebec
-
Sherbrooke、Quebec、カナダ、J1H 5H3
- Université de Sherbrooke - Campus de la santé
-
コンタクト:
- Guillaume Léonard, Ph.D.
- 電話番号:819-821-8000
- メール:guillaume.leonard2@usherbrooke.ca
-
コンタクト:
- Adrien Nourry
- 電話番号:+33611074458
- メール:adrien.nourry@usherbrooke.ca
-
主任研究者:
- Guillaume Léonard, Ph.D.
-
-
参加基準
適格基準
就学可能な年齢
- 大人
健康ボランティアの受け入れ
説明
Inclusion Criteria:
- Aged 18 to 35 years, inclusive
- Healthy
- Able to understand the study information and experimental procedures
- Able to provide informed consent
Exclusion Criteria:
- History of psychiatric disorders (including intellectual disability or severe cognitive, behavioral, or affective impairment) that could interfere with understanding the study or providing informed consent.
- History of neurological disorders, including epilepsy, stroke, brain or spinal cord surgery, or any neurological disease affecting motor or sensory function.
Inability to provide informed consent (e.g., dementia, significant hearing impairment, insufficient language proficiency).
- Any pain condition within the past 3 months, regardless of origin.
- Recent musculoskeletal injury or surgery within the past 3 months.
- Contraindications to transcranial magnetic stimulation (TMS), including a history of epilepsy or the presence of intracranial metallic objects, cochlear implants, or other non-removable metallic implants in or near the head.
- Use of analgesic or psychotropic medications.
- Individuals under legal guardianship or curatorship.
- Pregnant or breastfeeding women.
- Presence of a cardiac pacemaker or other implanted electronic medical device.
- Known allergy or previous skin reaction to capsaicin
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:基礎科学
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Experimental pain
Participants complete one experimental session.
Motor cortex excitability is first assessed at baseline using transcranial magnetic stimulation with electromyographic recordings from the first dorsal interosseous muscle.
Topical capsaicin cream is then applied to the forearm to induce temporary, moderate experimental pain.
Once pain is established, the same neurophysiological assessments are repeated during the pain condition.
|
Topical capsaicin cream (1%) is applied to the forearm to induce temporary, moderate experimental pain.
Motor cortex excitability is assessed before and during capsaicin-induced pain using transcranial magnetic stimulation.
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change in Short-Interval Intracortical Inhibition
時間枠:At baseline (before capsaicin cream application); at pain stabilization (after capsaicin cream application)
|
Short-interval intracortical inhibition will be assessed using paired-pulse transcranial magnetic stimulation over the primary motor cortex, with electromyographic recordings from the first dorsal interosseous muscle.
A subthreshold conditioning stimulus set at 80% of resting motor threshold will be followed by a suprathreshold test stimulus set at 120% of resting motor threshold, with an interstimulus interval of 3 ms.
Fifteen conditioned trials will be recorded for this measure.
The outcome will be expressed as the change in conditioned motor evoked potential amplitude relative to the unconditioned test response from pre- to post-application of topical capsaicin cream.
|
At baseline (before capsaicin cream application); at pain stabilization (after capsaicin cream application)
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change in Short-Interval Intracortical Facilitation
時間枠:At baseline (before capsaicin cream application); at pain stabilization (after capsaicin cream application)
|
Short-interval intracortical facilitation will be assessed using paired-pulse transcranial magnetic stimulation over the primary motor cortex, with electromyographic recordings from the first dorsal interosseous muscle.
A suprathreshold conditioning stimulus set at 120% of resting motor threshold will be followed by a subthreshold test stimulus set at 80% of resting motor threshold, with an interstimulus interval of 2 ms.
Fifteen conditioned trials will be recorded for this measure.
The outcome will be expressed as the change in conditioned motor evoked potential amplitude relative to the unconditioned test response from pre- to post-application of topical capsaicin cream.
|
At baseline (before capsaicin cream application); at pain stabilization (after capsaicin cream application)
|
|
Change in Pain Intensity
時間枠:From baseline through completion of the experimental session, an average of 2 hours
|
Pain intensity will be assessed using a visual analog scale ranging from 0 to 10, where 0 indicates no pain and 10 indicates the worst imaginable pain.
The outcome will be expressed as the change in pain intensity from pre- to post-application of topical capsaicin cream.
|
From baseline through completion of the experimental session, an average of 2 hours
|
|
Change in Intracortical Facilitation
時間枠:At baseline (before capsaicin cream application); at pain stabilization (after capsaicin cream application)
|
Intracortical facilitation will be assessed using paired-pulse transcranial magnetic stimulation over the primary motor cortex, with electromyographic recordings from the first dorsal interosseous muscle.
A subthreshold conditioning stimulus set at 80% of resting motor threshold will be followed by a suprathreshold test stimulus set at 120% of resting motor threshold, with an interstimulus interval of 15 ms.
Fifteen conditioned trials will be recorded for this measure.
The outcome will be expressed as the change in conditioned motor evoked potential amplitude relative to the unconditioned test response from pre- to post-application of topical capsaicin cream.
|
At baseline (before capsaicin cream application); at pain stabilization (after capsaicin cream application)
|
|
Change in Long-Interval Intracortical Inhibition
時間枠:At baseline (before capsaicin cream application); at pain stabilization (after capsaicin cream application)
|
Long-interval intracortical inhibition will be assessed using paired-pulse transcranial magnetic stimulation over the primary motor cortex, with electromyographic recordings from the first dorsal interosseous muscle.
A suprathreshold conditioning stimulus set at 120% of resting motor threshold will be followed by a suprathreshold test stimulus set at 120% of resting motor threshold, with an interstimulus interval of 100 ms.
Fifteen conditioned trials will be recorded for this measure.
The outcome will be expressed as the change in conditioned motor evoked potential amplitude relative to the unconditioned test response from pre- to post-application of topical capsaicin cream.
|
At baseline (before capsaicin cream application); at pain stabilization (after capsaicin cream application)
|
|
Change from baseline in corticospinal excitability
時間枠:At baseline (before capsaicin cream application); at pain stabilization (after capsaicin cream application)
|
Corticospinal excitability will be assessed using single-pulse transcranial magnetic stimulation applied over the primary motor cortex, with electromyographic recordings from the first dorsal interosseous muscle.
Single magnetic pulses of increasing intensity will be delivered to construct input-output recruitment curves for each participant.
Stimulation intensity will be increased in 5% steps, and 10 stimuli will be delivered at each intensity level.
Motor evoked potentials will be recorded using surface electromyography.
Input-output curves will be modeled using a Boltzmann sigmoidal function, and the slope, plateau, and S50 parameters will be extracted.
The outcome will be expressed as the change in these input-output curve parameters from pre- to post-application of topical capsaicin cream.
|
At baseline (before capsaicin cream application); at pain stabilization (after capsaicin cream application)
|
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
痛みに関連する痛みの破局的思考
時間枠:ベースライン
|
疼痛破局的思考は、痛みに関する破局的思考を測定するために設計された自己報告式質問票であるPain Catastrophizing Scaleの仏語カナダ版(PCS-CF)を使用して評価されます。
PCS-CFは、反芻思考、誇大視、無力感の3つの次元をカバーする13項目からなり、各項目は0(「全くない」)から4(「常にある」)までのリッカート尺度で評価されます。 項目スコアを合計して0から52の範囲の総合スコアを算出し、スコアが高いほど疼痛破局的思考が強いことを示します。 総合スコアが30以上の場合は、臨床的に有意なレベルの疼痛破局的思考を示す指標として提案されています。 |
ベースライン
|
|
Kinesiophobia
時間枠:Baseline
|
Kinesiophobia will be assessed using the French-Canadian version of the Tampa Kinesiophobia Questionnaire (EKT-CF).
It takes the form of a self-reported questionnaire of 17 items using a Likert scale ranging from 1 (strongly disagree) to 4 (strongly agree), with an acceptable degree of internal consistency (Cronbach's alpha = 0.71), satisfactory construct validity, and high sensitivity to change (intra-class correlation coefficient > 0.7).
The total score is obtained by adding the value of the responses and is between 17 and 68.
The value of 37/68 is considered as the threshold value at which kinesiophobia becomes significant.
|
Baseline
|
協力者と研究者
スポンサー
捜査官
- 主任研究者:Guillaume Léonard, Ph.D.、Université de Sherbrooke
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
その他の研究ID番号
- 2027-6267
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。